Abstract
The bacteria most commonly responsible for early-onset (materno-fetal) infections in neonates are group B streptococci, enterococci, Enterobacteriaceae and Listeria monocytogenes. Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, are the main pathogens in late-onset (nosocomial) infections, especially in high-risk patients such as those with very low birth-weight, umbilical or central venous catheters or undergoing prolonged ventilation. The primary objective of the paediatrician is to identity all potential cases of bacterial disease quickly and begin antibacterial treatment immediately after the appropriate cultures have been obtained.
Combination therapy is recommended for initial empirical treatment in the neonate. In early-onset infections, an effective first-line empirical therapy is ampicillin plus an aminoglycoside (duration of treatment 10 days). An alternative is ampicillin plus a third-generation cephalosporin such as cefotaxime, a combination particularly useful in neonatal meningitis (mean duration of treatment 14 to 21 days), in patients at risk of nephrotoxicity and/or when therapeutic monitoring of aminoglycosides is not possible. Another potential substitute for the aminoglycoside is aztreonam. Triple combination therapy (such as amoxicillin plus cefotaxime and an aminoglycoside) could also be used for the first 2 to 3 days of life, followed by dual therapy after the microbiological results. In late-onset infections the combination oxacillin plus an aminoglycoside is widely recommended. However, vancomycin plus ceftazidime (± an aminoglycoside for the first 2 to 3 days) may be a better choice. Teicoplanin may be a substitute for vancomycin. However, the initial approach should always be modified by knowledge of the local bacterial epidemiology.
After the microbiological results, treatment should be switched to narrower spectrum agents if a specific organism has been identified, and should be discontinued if cultures are negative and the neonate is in good clinical condition.
Penicillins and third-generation cephalosporins are generally well tolerated in neonates. There is controversy regarding whether therapeutic drug monitoring of aminoglycosides will decrease toxicity (particularly renal damage) in neonates, and on the efficacy and safety of a single daily dose versus multiple daily doses of these drugs. Toxic effects caused by vancomycin are uncommon, but debate still exists over the need for therapeutic drug monitoring of this agent.
When antibacterials are used in neonates, accurate determination of dosage is required, particularly for compounds with a low therapeutic index and in patients with renal failure. Very low birthweight infants are also particularly prone to antibacterial-induced toxicity.
Similar content being viewed by others
References
St Gerne III JW, Polin R. Neonatal sepsis. progress in diagnosis and management. Drugs 1988; 36(6): 784–800
Aujard Y. Neonatal infections — a special case? Res Clin Forums 1997; 19: 67–77
Saez-Llorens X, Vargas S, Guerra F, et al. Application of new sepsis definitions to evaluate outcome of pediatric patients with severe systemic infections. Pediatr Infect Dis 1995; 14: 557–61
Saez-Llorens X, McCracken GH. Clinical pharmacology of antibacterial agents. In: Remington JS, Klein JO, editors. Infectious disease of the fetus, newborn and infants. Philadelphia (PA): Saunders, 1995: 1287–336
Thompson PJ, Greenough A, Hird MF, et al. Nosocomial bacterial infections in very low birthweight infants. Eur J Pediatr 1992; 151: 451–4
Stoll BJ, Gordon T, Korones SB, et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129: 72–80
Baumgart S, Hall SE, Campos JM, et al. Sepsis with coagulase-negative staphylococci in critically newborns. Am J Dis Child 1983; 137: 461–3
Gouyon JB, Francoise C, Semama D, et al. Nosocomial sepsis due to Staphylococcus epidermidis and aureus in the newborn [in French]. Ann Pediatr 1990; 31: 21–5
Gaynes RP, Edwards JR, Jarvis WR, et al. Nosocomial infections among neonates in high-risk nurseries in the United States. Pediatrics 1996 Sep; 98(3): 357–61
Freeman RM, Ingram DL, Gross I, et al. A half century of neonatal sepsis at Yale. Am J Dis Child 1981; 135: 140–5
Bennet R, Eriksson M, Zetterstrom R. Increasing incidence of neonatal septicemia: causative organisms and predisposing risk factors. Acta Paediatr Scand 1981; 70: 207–10
Harris MC, Polin A. Neonatal septicemia. Ped Clin North Am 1983; 30(2): 243–58
Bhutta ZA, Naqvi SH, Muzaffer T, et al. Neonatal sepsis in Pakistan. Presentation and pathogens. Acta Paediatr Scand 1981; 80: 596–601
Tessin I, Trollfors B, Thiringer K. Incidence and etiology of neonatal septicemia and sepsis in Western Sweden 1975–1986. Acta Paediatr Scand 1990; 79(11): 1023–30
Giacoia PG. Uncommon pathogens in newborn infants. J Perinatol 1994; 14(2): 134–44
Feigin RD, McCracken GH, Klein J. Diagnosis and management of meningitis. Pediatr Infect Dis J 1992; 11: 785–814
Escobar GJ, Zukin T, Usatin MS, et al. Early discontinuation of antibiotic treatment in newborns admitted to rule out sepsis: a decision rule. Ped Infect Dis J 1994; 13: 860–6
Jackson MA, Shelton S, Nelson JD, et al. Relatively penicillin-resistant pneumococcal infections in pediatric patients. Pediatr Infect Dis 1984 Mar; 3(2): 129–32
Mehta G, Kumari S. Multi-resistant Staphylococcus haemolyticus in a neonatal unit in New Delhi. Ann Trop Paediatr 1997; 17(1): 15–20
Hieber JP, Nelson JD. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med 1977 Aug 25; 297(8): 410–3
de Louvois J, Blackbourn J, Hurley R, et al. Infantile meningitis in England and Wales: a two year study. Arch Dis Child 1991 May; 66(5): 603–7
Speer ME, Mason EO, Scharnberg JT. Cerebrospinal fluid concentrations of aqueous procaine penicillin G in the neonate. Pediatrics 1981 Mar; 67(3): 387–8
Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 1990; 19(4): 280–318
McCracken Jr GH, Ginsberg C, Chrane DF, et al. Clinical pharmacology of penicillin in newborn infants. J Pediatr 1973 Apr 1; 82(4): 692–8
Edwards MS. Antimicrobial therapy in pregnancy and neonates. Clin Perinatal 1997; 24(1): 91–105
Isaacs D, Wilkinson AR. Antibiotic use in the neonatal period. Arch Dis Child 1987; 62: 204–7
McCracken Jr GH, Kaplan JM. Penicillin treatment for congenital syphilis: a critical reappraisal. JAMA 1974 May 13; 228(7): 855–8
Speer ME, Taber LH, Clark DB, et al. Cerebrospinal fluid levels of benzathine penicillin G in the neonate. J Pediatr 1977 Dec 1; 9(6): 996–7
Klein JO, Scharberg MJ, Buntin M, et al. Levels of penicillin in serum of newborn infants after single intramuscular doses of benzathine penicillin G. J Pediatr 1973 Jun 1; 82(6): 1065–8
Kuigh M. Adverse drug reactions in neonates. J Clin Pharmacol 1994 Feb; 34(2): 128–35
Guignard JP. Drugs and the neonatal kidney. Dev Pharmacol Ther 1982; 4 (1 Suppl.): 19–27
Syriopoulou V, Bitsi M, Theodoridis C, et al. Clinical efficacy of sulbactam/ampicillin in pediatric infections caused by ampicillin-resistant or penicillin-resistant organisms. Rev Infect Dis 1981; 8 (5 Suppl.): 5630–3
Bingen E, Lambert-Zechovsky N, Guihaire E, et al. Importance of the study of the minimal bactericidal time of serum in the choice of optimal treatment of neonatal septicemias [in French]. Pathol Biol 1987 May; 35(5): 599–602
Daly JS, Dodge RA, Glew RH, et al. Effect of time and temperature on inactivation of aminoglycosides by ampicillin at neonatal dosages. J Perinatal 1997 Jan; 17(1): 42–5
Tessin I, Trollfors B, Thiringer K, et al. Ampicillin-aminoglycoside combinations as initial treatment for neonatal septicaemia or meningitis. A retrospective evaluation of 12 years’ experience. Acta Paediatr Scand 1991 Oct; 80(10): 911–6
Cooper MD, Keeney RE, Lyons SF, et al. Synergistic effects of ampicillin-aminoglycoside combination on group B streptococci. Antimicrob Agents Chemother 1979 Mar; 15(3): 484–6
Scheld WM, Alliegro GM, Field MR, et al. Synergy between ampicillin and gentamicin in experimental meningitis due to group B streptococci. J Infect Dis 1982; 146: 100–2
Toltzis P, Blumer JL. Antibiotic-resistant gram-negative bacteria in critical care setting. Ped Clin North Am 1995; 42(3): 687–702
Adam D. Beta-lactam antibiotics: their role in the management of infections in children. Ped Infect Dis J 1998; 17Suppl.:4–7
Burman LG, Berglund B, Huovinen P, et al. Effect of ampicillin versus cefuroxime on the emergence of beta-lactam resistance in faecal Enterobacter cloacae isolates from neonates. J Antimicrob Chemother 1993 Jan; 31(1): 111–6
Kalenic S, Francetic I, Polak J, et al. Impact of ampicillin and cefuroxime on bacterial colonization and infection in patients on a neonatal intensive care unit. J Hosp Infect 1993 Jan; 23(1): 35–41
Dahl LB, Melby K, Gutteberg TJ, et al. Serum levels of ampicillin and gentamicin in neonates of varying gestational age. Eur J Pediatr 1986 Aug; 145(3): 218–21
Kaplan JM, McCracken Jr GH, Horton HJ, et al. Pharmacologic studies in neonates given large dosages of ampicillin. J Pediatr 1974 Apr; 84(4): 571–7
Colding H, Moller S, Andersen GE. Continuous intravenous infusion of ampicillin and gentamicin during parenteral nutrition to 36 newborn infants using a dosage schedule. Acta Pediatr Scand 1984; 73: 203–9
Aujard Y. Antibiotic therapy in maternal-fetal infections [in French]. Ann Pediatr 1991; 38 (8 Suppl.): 539–43
Sutton AM, Turner TL, Cockburn F, et al. Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn. Rev Infect Dis 1986 Nov–Dec; 8 (5 Suppl.): 518S–522S
Sarff LD, McCracken Jr GH, Thomas ML, et al. Clinical pharmacology of methicillin in neonates. J Pediatr 1977 Jun; 90(6): 1005–8
Sarff LD, McCracken Jr GH. Methicillin-associated nephropathy or cystitis. Pediatrics 1977 Jun; 90(6): 1031–2
Mallouh AA. Methicillin-induced neutropenia. Pediatr Infect Dis 1985 May; 4(3): 262–4
Mitsuda T, Arai K, Fujita S, et al. Epidemiological analysis of strains of methicillin-resistant Staphylococcus aureus (MRSA) infection in the nursery; prognosis of MRSAcarrier infants. J Hosp Infect 1995 Oct; 31(2): 123–34
Fanos V, Verlato G, Dal Moro A, et al. Staphylococcus epidermidis isolation and antibiotic resistance in a neonatal intensive care unit. J Chemother 1995; 7(1): 26–9
Klein JF, Shahrivar F. Use of percutaneous silastic central venous catheters in neonates and the management of infectious complications. Am J Perinatol 1992 Jul; 9(4): 261–4
Banner Jr W, Gooch III WM, Burckart G, et al. Pharmacokinetics of nafcillin in infants with low birth weights. Antimicrob Agents Chemother 1980 Apr; 17(4): 691–4
Nahata MV, DeBolt SL, Powell DA. Adverse effects of methicillin, nafcillin and oxacillin in pediatric patients. Dev Pharmacol Ther 1982; 4(3–4): 117–23
Kitzing W, Nelson JD, Mohs E. Comparative toxicities of methicillin and nafcillin. Am J Dis Child 1981 Jan; 135(1): 52–5
Neu HC. Carbenicillin and ticarcillin. Med Clin North Am 1982 Jan; 66(1): 61–77
Steele RW. Infection in the immunocompromised host. Pediatr Infect Dis 1984; 4: 309–14
Nelson JD, McCracken Jr GH. Clinical pharmacology of carbenicillin and gentamicin in the neonate and comparative efficacy with ampicillin and gentamicin. Pediatrics 1973 Dec; 52(6): 801–12
Morehead CD, Shelton S, Kusmiesz H, et al. Pharmacokinetics of carbenicillin in neonates of normal and low birth weight. Antimicrob Agents Chemother 1972 Oct 1; 2(4): 267–71
Yoshioka H, Takimoto M, Shimizu T, et al. Pharmacokinetics of intramuscular carbenicillin in the newborn. Infection 1979 Jan; 7(1): 27–9
Nelson JD, Kusmiesz H, Shelton S, et al. Clinical pharmacology and efficacy of ticarcillin in infants and children. Pediatrics 1978 Jun; 61(6): 858–62
Nelson JD, Shelton S, Kusmiesz H. Clinical pharmacology of ticarcillin in the newborn infant: relation to age, gestational age, and weight. J Pediatr 1975 Sep; 87(3): 474–9
Sutherland R, Beale A, Boon RJ, et al. Antibacterial activity of ticarcillin in the presence of clavulanate potassium. Am J Med 1985 Nov; 79 Suppl. 5B: 13–24
Burstein AH, Wyble LE, Gal P, et al. Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis. Antimicrob Agents Chemother 1994 Sep; 38(9): 2024–8
Fricke G, Doerck M, Hafner D, et al. The pharmacokinetics of ticarcillin/clavulanate acid in neonates. J Antimicrob Chemother 1989 Nov; 24: (B Suppl.): 111B–120B
Mial-Hallen VM, Whitelaw AG, Darrel JH. Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimen in the treatment of early and late neonatal infections. Br J Clin Pract 1988; 42: 273–9
Drusano GL, Schimpff SC, Hewitt WL. The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis 1984 Jan 1; 6(1): 13–32
Adelman RD, Wirth F, Rubio T. A controlled study of the nephrotoxicity of mezlocillin and gentamicin plus ampicillin in the neonate. J Pediatr 1987 Dec; 111: 888–93
Bergan T. Review of the pharmacokinetics of mezlocillin. J Antimicrob Chemother 1983 May; 11 Suppl.: 1S–16S
Rubio T, Wirth F, Karotkin E. Pharmacokinetic studies of mezlocillin in newborn infants. J Antimicrob Chemother 1982 Jan; 9 (A Suppl.): 241S–244S
Janicke DM, Rubio TT, Wirth Jr FH, et al. Developmental pharmacokinetics of mezlocillin in newborn infants. J Pediatr 1984 May; 104(5): 773–81
Odio C, Threlkeld N, Thomas ML, et al. Pharmacokinetic properties of mezlocillin in newborn infants. Antimicrob Agents Chemother 1984 May; 25(5): 556–9
Placzek M, Whitelaw A, Want S, et al. Piperacillin in early neonatal infection. Arch Dis Child 1983 Dec; 58(12): 1006–9
Kacet N, Roussel Delvallez M, Gremillet C, et al. Pharmacokinetic study of piperacillin in newborns relating to gestational and postnatal age. Pediatr Infect Dis J 1992 May; (5): 365–9
Wilson CB, Koup JR, Opheim KE, et al. Piperacillin pharmacokinetics in pediatric patients. Antimicrob Agents Chemother 1982; 22: 442–5
Johnson GJ. Antibiotic induced hemostatic abnormalities. In: Peterson PK, Verhoef J, editors. The antimicrobial agents annual 1. Amsterdam: Elsevier, 1986: 408–23
Eichenwald HF, Schmidt HJ. The cephalosporin antibiotics in pediatric therapy. Eur J Pediatr 1986; 144: 532–8
de Louvois J, Mulhall A, James J. Cefuroxime in the treatment of neonates. Arch Dis Child 1982; 57: 59–62
Dajani AS. Cefotaxime — safety, spectrum and future prospects. Res Clin Forums 1997; 19(7): 57–64
Dajani AS, Pokowsky LH. Delayed cerebrospinal fluid sterilization, in vitro bactericidal activities and side effects of selected beta-lactams. Scand J Infect Dis 1990; 731 Suppl.: 31S–42S
Cataldi L, Fanos V. Neonatal urinary tract infections: diagnosis and treatment. In: Cataldi L, Fanos V, Simeoni U, editors. Neonatal nephrology in progress. Lecce: Agorà, 1996: 183–98
Gaudelus J. Preventive treatment of infants’ urinary tract infections [in French]. Arch Pediatr 1998; 5 (3 Suppl.): 303–11
Cataldi L, Cianfoni A. Urinary tract infections in the newborn and infant [in Italian]. Med Surg Pediatr 1997; 19: 319–23
Mangiarotti P, Pizzini C, Fanos V. Antibiotic prophylaxis in children with relapsing urinary tract infections. J Chemother. In press
Brumfitt W, Hamilton-Miller JMT. A comparative trial of low dose cefaclor and macrocrystallin nitrofurantoin in the prevention of recurrent urinary tract infection. Infection 1995; 23: 98–102
Nord CE, Heimdahl A, Lundberg C, et al. Impact of cefaclor on the normal oropharingeal and intestinal microflora. Scand J Infect Dis 1987; 19: 681–5
Nord CE, Edlund C. Impact of antimicrobial agents on human intestinal microflora. J Chemother 1990; 2: 218–37
Gerard M, Diakite B, Bedu A. Urinary infection in the newborn [in French]. Arch Pediatr 1998; 5 (3 Suppl.): 254–9
Brumfitt W, Hamilton-Miller JMT. Cefaclor into the millennium. Chemother 1999; 11(3): 163–178
Del Rio M, McCracken GH, Nelson GH, et al. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of patients with bacterial meningitis. Antimicrob Agents Chemother 1982; 22: 621–7
Begue P, Safran C, Quinion F, et al. Comparative pharmacokinetics of four new cephalosporins: moxalactam, cefotaxime, cefoperazone and ceftazidime in neonates. Dev Pharmacol Ther 1984; 7 (1 Suppl.): 105–8
Cunha BA. Third generation cephalosporines: a review. Clin Ther 1992; 14: 616–52
Mc Cracken GH. Use of third generation cephalosporins for treatment of neonatal infections. Am J Dis Child 1985; 139: 1079–80
Kaplan SL. Serious pediatric infections. Am J Med 1990; 88 (4A Suppl.): 18S–24S
Puthicheary SD, Goldsworthy PJ. Ceftazidime and cefotaxime — the clinician’s choice. Clin Ther 1984; 11(2): 186–204
de Louvois J. Special antibacterial problems in the neonate. Res Clin Forums 1986; 8(4): 79–95
de Louvois J. Acute bacterial meningitis in the newborn. J Antimicrob Chemother 1994; 34 (A Suppl.): 61–73
Word BM, Klein JO. Current therapy of bacterial sepsis and meningitis in infants and children: a pool of directors of programs in pediatric infection diseases. Pediatr Infect Dis J 1988; 7: 267–70
Klass PE, Klein JO. Therapy of bacterial sepsis, meningitis and otitis media in pediatric infectious diseases. Pediatr Infect Dis J 1992; 11: 702–7
Jones RN, Barry AL. Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime and cefotaxime-desacetylcefotaxime in presence of human serum. Antimicrob Agents Chemother 1987; 31: 818–20
Jacobs RF. Cefotaxime treatment of gram-negative enteric meningitis in infants and children. Drugs 1988; 35: 185–9
Sykes RB, Bonner BP, Swabb EA. Modern betalactam antibiotics. Pharmacol Ther 1985; 29: 321–52
Shaad VB, Hayton W, Stoeckel K. Single-dose ceftriaxone kinetics in the newborn. Clin Pharmacol Ther 1985: 37: 522–8
Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins: an update. Drug Saf 1993; 9(2): 132–42
Fernandez-Guerrero M, Gudial F, Rodriguez-Torres A, et al. Nosocomial pneumonia: comparative multicenter trial between monotherapy with cefotaxime and treatment with antibiotic combinations. Infection 1991; 19: 320–5
Meyers BR. Comparative toxicities of third generation cephalosporins. Am J Med 1985; 79 (A Suppl.): 96–103
Jacobs RF, Darville T, Parks JA. Safety profile and efficacy of cefotaxime for the treatment of hospitalized children. Clin Infect Dis 1992; 14: 56–65
Feketty FR. Safety of parenteral third generation cephalosporins. Am J Med 1990; 88 Suppl.: 38S–44S
Norrby SR. Adverse reactions and interactions with newer cephalosporins and cephamycin antibiotics. Med Toxicol 1986; 1(1): 32–46
McCracken GH, Nelson JD, Kaplan SL, et al. Consensus report: antimicrobial therapy for bacterial meningitis in infants and children. Pediatr Infect Dis J 1987; 6: 501–5
Chartrand SA, Marks MI, Scribner RK, et al. Moxalactam therapy of Haemophilus influenzae type B meningitis in children. J Pediatr 1984; 104: 454–9
Kaplan SL, Mason ED, Masak SK, et al. Prospective comparative trial of moxalactam versus ampicillin and chloramphenicol for treatment of Haemophilus influenzae type B meningitis in children. J Pediatr 1984; 104: 447–53
Bernini JC, Mustafa MM, Sutor LJ, et al. Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia. J Pediatr 1995; 126: 813–5
Lascari AD, Amyot KA. Fatal hemolysis caused by ceftriaxone. J Pediatr 1995; 126:816–7
Aronson B, Mollby R, Nord CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiologic data from Sweden. J Inf Dis 1985; 151: 476–81
Jacobs RF. Ceftriaxone-associated cholecystitis. Pediatr Infect Dis J 1988; 7: 434–6
Tune BM, Fravert D. Mechanism of cephalosporin nephrotoxicity: a comparison of cephaloridine and cephaloglicyn. Kidney Int 1980; 18: 591–600
Silverblatt F. Pathogenesis of nephrotoxicity of cephalosporins and aminoglycosides: a review of current concepts. Review Infect Dis 1982; 4: 360–5
Mannion JC, Block R, Popovich NG. Cephalosporin-aminoglycoside synergistic nephrotoxicity: fact or fiction? Drug Intell Clin Pharm 1981; 15: 248–55
Tune BM. Renal tubular transport and nephrotoxicity of betalactam antibiotics: structure-activity relationship. Miner Electrol Metab 1994; 20: 221–31
Kaloyanides GJ. Antibiotic-related nephrotoxicity. Nephrol Dial Transplant 1994; 9 (4 Suppl.): 130S–134S
Daghero O, Andreoni G, Arione R. Cephalosporins and enzymuria [in Italian]. Minerva Med 1986; 77: 231–7
Tune BM. Nephrotoxicity of beta-lactam antibiotics: mechanism and strategies for prevention. Pediatr Nephrol 1997 Dec; 11(6): 768–72
Mondorf AW, Burk P, Stevanescu P, et al. Effects of cefotaxime on the proximal tubules of human kidney. J Antimicrob Chemoth 1980; 6 (A Suppl.): 155–9
Kuhlmann J. Renal safety of new broad-spectrum antibiotics [in German]. Munch Med Wschr 1983; 125 (2 Suppl.): 212–22
Hartman HG, Sutzler GA, Istrighans H, et al. Renal tolerance of cefotaxime after the surgical intervention. Clin Trials J 1983; (9): 327–39
Ninane G. Cefotaxime (HR 756) and nephrotoxicity [letter]. Lancet 1979 Feb 10; I(1881): 332
Spritzer R, Kamp N, Dzolic G, et al. Five years of cefotaxime use in a neonatal intensive care unit. Pediatr Infect Dis J 1990; 9: 92–6
Kasama R, Sorbello A. Renal and electrolyte complications associated with antibiotic therapy. Am Fam Physician 1996; 53 (1 Suppl.): 227S–232S
Padovani EM, Fanos V, Boner A, et al. Clinical efficacy and tolerance of ceftazidime as sole antibiotic in neonatal infections. Clin Trials J 1985; 3: 224–30
Tune BM. The nephrotoxicity of cephalosporin antibiotics: structure-activity relationships. Comm Toxicol 1986; 1: 145–7
Fanos V, Fostini R, Panebianco A. Ceftazidime in common pediatric infections: experience on 262 cases [in Italian]. Clin Ter 1991; 13: 327–32
Cecconi M, Manfredi R, Cecarin L, et al. Early indicators of nephrotoxicity: comparison of two antibiotics. Int J Clin Pharm Ther Toxicol 1987; 25: 452–7
Fanos V, Fostini R, Chiaffoni GP, et al. Ceftazidime: clinical efficacy, antibacterial activity and tolerance in the treatment of neonatal infections. Curr Ther Res 1985; 38: 640–5
Fanos V, Padovani EM, Benoni G, et al. Laboratory diagnostic of renal damage in preterm newborns [in Italian]. Acta Pediatr Lat 1990; 43(2): 124–31
Kissling M, Ruch W, Fernex W. Ceftriaxone in pediatric patients: an analysis of 4743 cases described in literature. Med Press 1988; 4: 1–7
Chu ML, Wang CC, Ho LJ. Once daily ceftriaxone for the treatment of meningitis and other serious infections in children. Med Press 1988; 4: 8–12
Wiese G. Treatment of neonatal sepsis with ceftriaxone/gentamicin and with azlocillin/gentamicin. A clinical comparison of efficacy and tolerability. Chemotherapy 1988; 34: 158–63
Bradley JS, Ching DLK, Wilson TA, et al. Once daily ceftriaxone to complete therapy of uncomplicated Group B streptococcal infection in the neonate. Clin Pediatr 1992 May; 274–8
Shaad VB. The cephalosporin compounds in severe neonatal infections. Eur J Pediatr 1984; 14: 143–6
Bryan CS, John FR, Pai MS, et al. Gentamicin versus cefotaxime in the therapy of neonatal sepsis. Am J Dis Child 1985; 139: 1086–9
Modi N, Damjianovich V, Cooke RWI. Outbreak of cephalosporin resistant Enterobacter cloacae infection in a neonatal intensive care unit. Arch Dis Child 1987; 62: 148–51
Finnstrom O, Isaksson B, Haeggman S, et al. Control of an outbreak of a highly beta-lactam-resistant Enterobacter cloacae strain in a neonatal special care unit. Acta Paediatr 1998 Oct; 87(10): 1070–4
Richards DM, Brogden RN. Ceftazidime. A review of its antibacterial activity, pharmacokinetics properties and therapeutic use. Drugs 1985; 29: 105–61
de Louvois J, Dagan R, Tessin I. A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. Eur J Pediatr 1992; 151(12): 876–84
Snelling S, Hart CA, Cooke RW Ceftazidime or gentamicin plus benzylpenicillin in neonates less than forty eight hours. J Antimicrob Chemother 1983; 12 (A Suppl.): 353–6
Pollock I, Mulhall A, de Louvois J. Ceftazidime in the treatment of neonatal infections. J Hosp Infect 1985; 6: 158–65
Low DC, Bissenden JG, Wise R, Ceftazidime in neonatal infections. Arch Dis Child 1985; 60: 360–4
Amato M, Shaad UB. Preliminary experience with ceftazidime monotherapy in perinatal infections. Helv Paediatr Acta 1987; 42: 297–303
Fink S, Karp W, Robertson A. Ceftriaxone effect on bilirubinalbumin binding. Pediatrics 1987; 80: 873–5
Wadsworth JJ, Suh B. In vivo displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycine in newborns. Antimicrob Agents Chemother 1988; 32: 83–7
Robertson A, Fink S, Karp W. Effect of cephalosporins on bilirubin-albumin binding. J Pediatr 1988; 112(2): 291–4
Del Rio MA, Chrone DF, Shelton S, et al. Ceftriaxone versus ampicillin and chloramphenicol for the treatment of bacterial meningitis in children. Lancet 1983; I: 1241–4
Lebel MH, McCracken GH. Aztreonam: review of the clinical experience and potential uses in pediatrics. Pediatr Infect Dis J 1988; 7: 331–9
Bosso JA, Black PG. The use of aztreonam in pediatric patients: a review. Pharmacotherapy 1991; 11: 20–5
Brodgen R, Heel RC. Aztreonam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986; 31: 96–130
Millar MR, Gorham P, Baxter H, et al. Pharmacokinetics of aztreonam in very low birthweight neonates. Eur J Clin Microbiol 1987; 6: 691–2
Likitnukul S, McCracken GH, Threlkeld N, et al. Pharmacokinetics and plasma bactericidal activity of aztreonam in low-birth-weight infants. Antimicrob Agents Chemother 1987; 31: 81–3
Stutman HR, Marks MI, Swabb EA, et al. Single-dose pharmacokinetics of aztreonam in pediatric patients. Antimicrob Agents Chemother 1984; 26(2): 196–8
Borderon JC, Rostegar A, Ramponi N, et al. Effects of aztreonam on aerobial fecal flora of the infant [in French]. Pathol Biol 1987; 35: 665–8
Uauy R, Mire C, Argyle R, et al. Metabolic tolerance to arginine: implications for the safe use of arginase salt-aztreonam combination in the neonatal period. J Pediatr 1991; 118: 965–70
Sklavunu-Tsurutsoglu S, Gatzola-Karaveli M, Hatziioannidis K, et al. Efficacy of aztreonam in the treatment of neonatal sepsis. Rev Infect Dis 1991; 13 Suppl.: 591S–593S
Costantanopoulos A, Thomaidou L, Loupa H, et al. Successful response of severe neonatal Gram-negative infection to treatment with aztreonam. Chemotherapy 1989; 35 (1 Suppl): 101S–105S
Cuzzolin L, Fanos V, Zambreri D, et al. Pharmacokinetics and renal tolerance of aztreonam in premature infants. Antimicrob Agents Chemother 1991; 35: 1726–8
Umaña MA, Odio CM, Castro E, et al. Evaluation of aztreonam and ampicillin versus amikacin and ampicillin for treatment of neonatal bacterial infections. Pediatr Infect Dis J 1990; 9: 175–80
Neu HC. Why carbapenems? Curr Opin Infect Dis 1994; 7 (1 Suppl.): 3S–10S
Blumer JL. Pharmacokinetic determinants of carbapenem therapy in neonates and children. Pediatr Infect Dis J 1996 Aug; 15(8): 733–7
Clissold SP, Todd PA, Campoli-Richards DM. Imipenem/ cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1987 Mar; 33(3): 183–241
Freij BJ, McCracken Jr GH, Olsen KD, et al. Pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother 1985 Apr; 27(4): 431–5
Gruber WC, Rench MA, Garcia-Prats JA, et al. Single-dose pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother 1985 Apr; 27(4): 511–4
Begue P, Baron S, Challier P. Pharmacokinetics and clinical evaluation of imipenem/cilastatin in children and neonates. Scand J Infect Dis 1987; 52 Suppl.: 40–5
Collins MA, Tolpin M, Collaborative Imipenem-Cilastatin Study Group. Clinical evaluation of imipenem-cilastatin as a single agent therapy for sepsis neonatorum [abstract]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1987: 188
Eng RH, Munsif AR, Yangco BG, et al. Seizure propensity with imipenem. Arch Intern Med 1989 Aug 1; 149(8): 1881–3
Arrietta A. Use of meropenem in treatment of serious infections in children: review of current literature. Clin Infect Dis 1997 Feb; 24 Suppl. 2: 207S–212S
Bradley JS. Meropenem: a new extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics. Pediatr Infect Dis J 1997; 16:263–8
Blumer JL, Reed MD, Kearns GL, et al. Sequential, single-dose pharmacokinetics evaluation of meropenem in hospitalized infants and children. Antimicrob Agents Chemother 1995; 39: 1721–5
Ford DM. Basic mechanism of aminoglycoside nephrotoxicity. Pediatr Nephrol 1994; 8(5): 635–6
Borderon JC, Langer J, Ramponi N, et al. Survey of antibiotic therapies in pediatric intensive care units [in French]. Ann Pediatr 1992; 39: 27–36
Craig WA. Postantibiotic effects on experimental infection models: relationship to in vitro phenomena and to treatment of infection in man. J Antimicrob Chemother 1993; 31: 149–58
Besunder JB, Reed MD, Blumer JD. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface. Part II. Clin Pharmacokinet 1988; 14: 261–86
Langhendries JP, Battisti O, Bertrand JM. Aminoglycoside nephrotoxicity and urinary excretion of N-acetyl-beta-D-glucosaminidase. Biol Neonate 1988; 53: 253–9
Aujard Y. Gentamicin in pediatrics [in French]. Ann Pediatr 1987; 34(9): 677–85
Siber GR, Smith AL, Levin MJ. Predictability of peak serum concentration with dosage based on body surface area. J Pediatr 1979; 94(1): 135–8
Granati B, Assael, BM, Chung M, et al. Clinical pharmacology of netilmicin in preterm and term newborn infant. J Pediatr 1985; 106: 664–6
Kenyon CF, Knoppert DC, Lee SK, et al. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infants. Antimicrob Agents Chemother 1990 Feb; 34(2): 265–8
de Haag M, Shoemaker RC, Mouton JW, et al. Tobramycin pharmacokinetics in neonates. Clin Pharmacol Ther 1997; 62(4): 392–9
Kasik JW, Jenkins S, Lenshen MP, et al. Postconceptonal age and gentamicin elimination half-life. J Pediatr 1985; 106: 502–5
Semchuck WN, Shevchuck YM, Sankaron K, et al. Prospective, randomized, controlled evaluation of a gentamicin loading dose in neonates. Biol Neonate 1995; 67: 13–20
Cordero L, Arwood L, De Cenzo J, et al. Serum netilmicin levels in premature AGA infants. Am J Perinatol 1984; 4(1): 36–40
Assael BM, Parini R, Rusconi F, et al. Influence of intrauterine maturation on the pharmacokinetics of amikacin in the neonatal period. Pediatr Res 1982; 16: 810–5
Padovani EM, Pistolesi C, Fanos V, et al. Pharmacokinetics of amikacin in neonates. Dev Pharmacol Ther 1993; 20: 167–73
Williams BJ, Ransom JL, Gal P, et al. Gentamicin pharmacokinetics in neonates with patent ductus arteriosus 1997; 25: 273–5
Zarfin Y, Koren G, Maresky D et al. Possible indomethacin-aminoglycoside interactions in preterm infants. J Pediatr 1985; 106: 511–2
Kalenga M, Devos D, Moulin D, et al. The need for pharmacokinetic monitoring of gentamicin therapy in critically ill neonates. Dev Pharmacol Ther 1984; 7 (1 Suppl.): 130–4
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–9
Paap CM, Bosso JA. Treatment options for the pharmacologic therapy of neonatal meningitis. Drugs 1992; 43(5): 700–12
Sawyers CL, Moore RD, Lerner SA, et al. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis 1986; 153: 1062–8
Itsarayoungyuen S, Riff L, Schanb V. Tobramicin and gentamicin are equally safe for neonates: results of a double-blind randomized trial with quantitative assessment of renal function. Pediatr Pharmacol 1982; 2: 143–55
Padovani EM, Fanos V, Benoni G, et al. Urinary excretion of alanine-aminopeptidase and N-acetyl-beta-D-glucosaminidase in preterm neonates on antibiotic therapy. Clin Trials J 1988; 25(4): 266–76
Ismail R, Hag AR, Azman M, et al. Therapeutic drug monitoring of gentamicin: a 6 year follow-up audit. J Clin Pharm Ther 1997; 22(1): 21–5
Conroy S. Unlicensed and off label drug use for pediatric patients. Optimal dosing schedules are needed for premature infants. BMJ 1998 Jul 18; 317(7152): 204–5
Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infection. Lancet 1993; 341:335–9
Hock R, Anderson RJ. Prevention of drug-induced nephrotoxicity in the intensive care unit. J Crit Care 1995 Mar; 10(1): 33–43
Springate JE. Toxic nephropathies. Curr Opin Pediatr 1997; 9: 166–9
Deamer R, Dial L. The evolution of aminoglycoside therapy: a single daily dose. Am Fam Physician 1996; 53: 1782–6
Hatala R, Dinh R, Cook D. Once daily aminoglycoside dosing in immunocompetent adults: a metaanalysis. Ann Intern Med 1996; 124:717–24
Barza M, Joannidis JPA, Cappelleri JC, et al. Single or multiple daily doses of aminoglycoside. BMJ 1996; 312: 338–45
Skopnik H, Heinaman G. Once daily aminoglycoside regimens in full term neonates. Pediatr Infect Dis J 1995; 14: 71–2
Campbell H. Single or multiple daily doses of aminoglycoside: more details needed of treatment in neonates and young children [letter]. BMJ 1996; 313: 490; discussion 490-1
Colding H, Brygge K, Brendstrup L, et al. Enzymuria in neonates receiving continuous intravenous infusion of gentamicin. APMIS 1992; 100: 119–24
Skopnik H, Wallraf R, Nies B, et al. Pharmacokinetics and antibacterial activity of daily gentamicin. Arch Dis Child 1992; 67: 57–61
Bingen E, Lambert-Zekowsky N, Aujard Y Determination of aminoglycosides in the newborn infant. Significance and methods [in French]. Pediatrie 1986; 41(2): 135–45
Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions of gentamicin in burn patients. J Pharmacokinet Biopharm 1976; 4: 183–95
Padovani EM, Fanos V, Pistolesi C. Computerized monitoring of amikacin plasma concentrations in neonates [in Italian]. Neonatologica 1992; 3: 163–70
Simkin [computer program]. Release 4. 1. Gainesville (FL): Simkin Inc, 1991
Fanos V, Pistolesi C, Rugolotto S, et al. Aminoglycosides in preterm newborns: computerized optimization of therapy. J Chemother 1993; 5 (1 Suppl.): 463S–464S
Messori A, Bosi A, Guidi S, et al. PKRD — a pharmacokinetic program for least squares and bayesian analysis of repeated-dose pharmacokinetic curves. Comput Programs Biomed 1985; 19: 167–77
Steele RW, Kearns GL. Antimicrobial therapy for pediatric patients. Pediatr Clin North Am 1989; 36(5): 1321–49
Hoitsma JA, Wetzeis JFM, Koene R. Drug-induced nephrotoxicity. Aetiology, clinical features and management. Drug Saf 1991; 6(2): 131–47
Eisenberg JM, Koffer H, Glick A, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107: 900–9
Destache CJ, Meyer SK, Padomek MT, et al. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections. Ann Pharmacother 1989; 23: 33–8
Fanos V, Cataldi L. Aminoglycoside-induced nephrotoxicity in the newborn. In: Cataldi L, Fanos V, Simeoni U, editors. Neonatal nephrology in progress. Lecce: Agora, 1996: 152–81
Khoory BJ, Fanos V, Dall’Agnola A, et al. Aminoglycosides, risk factors and neonatal kidney [in Italian]. Med Surg Pediatr 1996; 18: 495–9
Humes DH. Aminoglycoside nephrotoxicity. Kidney Int 1988; 33: 900–11
Moestrup S, Cin S, Varum C, et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995; 96: 1404–13
Elinder G, Aperia A. Development of glomerular filtration rate and excretion of beta-2 microglobulin in neonates during gentamicin treatment. Acta Paediatr Scand 1983; 219–24
Gordjani N, Burghard R, Muller L, et al. Urinary excretion of adenosine deaminase binding protein in neonates treated with tobramycin. Pediatr Nephrol 1995; 9: 419–22
Gouyon JB, Aujard Y, Abisron A, et al. Urinary excretion of N-acetyl-beta-glucosaminidase and beta-2-microglobulin as early markers of gentamicin nephrotoxicity in neonates. Dev Pharmacol Ther 1987; 10: 145–52
Fanos V, Mussap M, Verlato G, et al. Evaluation of antibiotic-induced nephrotoxicity in preterm newborns by determining urinary alpha-1 microglobulin. Pediatr Nephrol 1996; 10: 645–7
Mussap M, Fanos V, Cataldi L, et al. Urinary low molecular mass proteins and enzymes as early, non invasive markers of nephrotoxicity in the neonate. Eur J Lab Med 1998; 6(1): 1–14
Ibrahim S, Langhendries JP, Bernard A. Urinary phospholipids excretion in neonates treated with amikacin. Int J Clin Pharmacol Res 1994; 14: 149–53
Giapros VI, Andronikou S, Cholesas VI, et al. Renal function in premature infants during aminoglycoside therapy. Pediatr Nephrol 1995; 9(2): 163–6
Fisher DA, Lakshmanan J. Metabolism and effects of epidermal growth factor and related growth factors in mammals. Endocr Rev 1990; 11(3): 418–42
Humes HD, Lake EW, Liu S. Renal tubule cell repair following acute renal injury. Miner Electrol Metab 1995; 21: 353–65
Watanabe K, Ono A, Hirata Y, et al. Maturational changes and origin of urinary human epidermal growth factor in the neonatal period. Biol Neon 1989; 56: 241–5
Sereni F, Assael BM, Melzi ML. Drugs, kidney, development [in Italian]. Italian J Pediatr 1988; 14: 463–73
Gilbert T, Nabarra B, Merlet-Benichou C. Light- and electron-microscopy analysis of the kidney in newborn rats exposed to gentamicin in utero. Am J Pathol 1988; 130: 33–43
Smaoui H, Mallié JP, Cheignon M, et al. Glomerular alterations in rat neonates after transplacental exposure to gentamicin. Nephron 1991; 59: 626–31
Smaoui H, Schaeverbeke M, Mallié JP, et al. Transplacental effects of gentamicin on endocytosis in rat renal proximal tubular cells. Pediatr Nephrol 1994; 8(4): 447–50
Lehly DJ, Braun BI, Tholl DA, et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy? J Am Soc Nephrol 1993; 4(1): 81–90
Tsukahara H, Yoshimoto M, Saito M, et al. Assessment of tubular function in neonates using urinary beta-2 microglobulin. Pediatr Nephrol 1990; 4: 512–4
Tack ED, Perlman JM, Robson AM. Renal injury in sick newborn infants: a prospective evaluation using urinary beta-2 microglobulin concentrations. Pediatrics 1988; 81(3): 432–40
Guignard JP, Torrado A, Mazouni JM, et al. Renal function in respiratory distress syndrome. J Pediatr 1976; 88(5): 845–50
Zanardo V, Da Rial R, Faggian D, et al. Urinary beta 2 microglobulin excretion in prematures with respiratory distress syndrome. Child Nephrol Urol 1990; 10: 135–8
Aperia A, Broberger V β2-Microglobulin as indicator of renal tubular maturation and disfunction in the newborn. Acta Pediatr Scand 1979; 68: 669–76
Padovani EM, Fanos V, Di Martino R, et al. Hyperbilirubinemia, phototherapy and tubular renal function in preterm newborn [in Italian]. Neonatologica 1989; 3(1): 27–31
Zager RA. Endotoxemia, renal hypoperfusion and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure. Am J Kidney Dis 1992; 20(3): 223–30
Spiegel DM, Shanley PF, Molitoris BA. Mild ischemia predisposes the S3 segment to gentamicin toxicity. Kidney Int 1990; 38: 459–64
Adelman RD, Spangler WL, Beason F. Furosemide enhancement of experimental nephrotoxicity: comparison of functional and morphological changes with activities of urinary enzymes. J Infect Dis 1979; 140: 340–2
Gouyon JB, Guignard JP. Rein et diuretiques. Progr Neonatol 1988; 8: 224–57
Dufful SB, Begg EJ. Vancomycin toxicity. What is the evidence for dose dependency? Adverse Drug React Toxicol Rev1994; 13(2): 103–14
Kunin GD. Clinical nephrotoxicity of tobramycin and gentamicin. JAMA 1980; 244(16): 1808–10
Henriksson P, Nils W, Suhlin I, et al. Netilmicin in moderate to severe infections in newborns and infants: a study of efficacy, tolerance and pharmacokinetics. Scand J Dis Child 1973; 125: 656–60
Kaplan JM, Mc Cracken GHJ, Thomas ML, et al. Clinical pharmacology of tobramycin in newborns. Am J Dis Child 1973; 125: 656–60
Andersen JB, Rosdahl N, Veisgaard R. Aspects of pharmacology of gentamicin in newborns infants. Acta Paediatr Scand 1972; 61: 656–60
McCracken Jr GH, Gay Jones L. Gentamicin in the neonatal period. Am J Dis Child 1970; 120: 524–33
Howard JB, McCracken Jr GH, Trujillo H, et al. Amikacin in newborn infants: comparative pharmacology with kanamicin and clinical efficacy in 45 neonates with bacterial disease. Antimicrob Agents Chemother 1976; 10: 205–10
Tessin I, Trollfors B, Bergmark J, et al. Enzymuria in neonates during treatment with tobramycin of ceftazidime. Pediatr Infect Dis J 1988; 7: 142–3
Rajchgot P, Prober CG, Soldin S, et al Aminoglycoside related nephrotoxicity in the premature newborn. Clin Pharmacol Ther 1984; 35(3): 394–401
Lewis DA, Reeves DS. Antibiotics at extreme ages: choice and constraints. J Antimicrob Chemother 1994, 34 (A Suppl.): 11–8
McCracken G. Aminoglycoside toxicity in infants and children. Am J Med 1986 Jun; 80 (6B Suppl.): 172–8
Pittinger CB, Eryaness YI, Adamson R. Antibiotic-induced paralysis. Anesth Analg 1970; 49: 487–501
Grunenberg RN, Wilson APR. Anti-infective treatment in intensive care: the role of glycopeptides. Intensive Care Med 1994; 20 (4 Suppl.): 17S–22S
Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316(15): 927–31
Cercenado E, Garcìa-Leoni ME, Diaz MD, et al. Emergence of teicoplanin-resistant coagulase-negative staphylococci. J Clin Microbiol 1996; 34(7): 1765–8
Rodvold KA, Everett JA, Pryka RD, et al. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clin Pharmacokinet 1997 Jul; 33(1): 32–51
Fanos V, Kacet N, Mosconi G. A review of teicoplanin in the treatment of serious neonatal infections. Eur J Pediatr 1997; 156: 423–7
Fanos V, Benini D, Vinco S, et al. Glycopeptides and the neonatal kidney [in Italian]. Med Surg Pediatr 1997; 19: 259–62
Tarral E, Jehl F, Tarral A, et al. Pharmacokinetics of teicoplanin in children. J Antimicrob Chemoth 1988; (A Suppl.): 45S-51S
Terragna A, Ferrea G, Loy A, et al. Pharmacokinetics of teicoplanin in pediatric patients. Antimicrob Agents Chemother 1988; 32: 1223–6
Mullet MD, Cook EF, Gallagher R. Nosocomial sepsis in the neonatal intensive care unit. J Perinatol 1998; (2): 112–5
Freeman J, Goldmann DA, Smith NE, et al. Association of intravenous lipid emulsion and coagulase-negative staphylococcal bacteriemia in neonatal intensive care unit. N Engl J Med 1990; 323(5): 301–8
Rodvold KA, Gentry CA, Plank GS, et al. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995; 17: 239–46
Schaad UB, McCracken GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. Pediatrics 1988; 96: 119–26
McDougall A, Ling EW, Levine M, et al. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit 1995; 17(4): 319–26
Hardenbrook M, Kildoo CW, Gennrich JL, et al. Prospective evaluation of a vancomycin dosage guideline for neonates. Clin Pharm 1991; 10: 129–32
Pawlosky F, Thomas A, Kergueris MF, et al. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Br J Clin Pharmacol 1998 Aug; 46(2): 163–7
Prober CG, Stevenson DK, Benitz WE. The use of antibiotics in neonates weighting less than 1200 grams. Pediatr Infect Dis J 1990; 9: 111–21
Cantu TG, Yamanaka S, Yuen NA, et al. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533–43
Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there. Clin Infect Dis 1994; 18: 544–6
Phillips G, Golledge C. Vancomycin and teicoplanin: something old, something new. Med J Austr 1992; 156: 53–7
Janet RV, Marinkovich GA, Gayle EL. Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing intervals in preterm infants. Pediatr Infect Dis J 1993; 12: 156–7
Naqvi SH, Keenan WJ, Reichley RM, et al. Vancomycin pharmacokinetics in small seriosly ill infants. Am J Dis Child 1986; 140: 107–9
Borderon JC, Laugier J, Chamboux C, et al. Continuous infusion of vancomycin in newborn infants [in French]. Pathol Biol 1994; 42(5): 525–9
Faber BT, Modelliring RC. Retrospective study of the toxicity of preparation of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1985; 23: 138–41
Chow AW, Azar RW Glycopeptides and nephrotoxicity. Intensive Care Med 1994; 20: 523–9
Dean RP, Wagner DJ, Toplin MD. Vancomycin/aminoglycoside toxicity. J Pediatr 1986; 106: 861–2
Goetz MB, Sayers J. Nephrotoxicity ofvancomycin and aminoglycoside therapy, separately and in combination. J Antimicrob Chemother 1993; 32: 325–34
Rybak MJ, Albrecht LS, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679–87
Shackley F, Roberts P, Health P, et al. Trough only monitoring of serum vancomycin concentration in neonates. J Antimicrob Chemother 1998; 41: 141–2
Nakata MC. Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy. Chemotherapy 1987; 33: 302–4
Goren MP, Baker DKJ, Shenep JL. Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J 1989; 8: 278–82
Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity: a review. Med Toxicol 1988; 3: 376–86
Shaad UB, Nelson JD, McCracken GH. Pharmacology and efficacy of vancomycin for staphylococcal infections in children. Rev Infect Dis 1981; 3 Suppl.: 282S–288S
Wallace MR, Mascola JR, Oldfield III EC. Red man syndrome: incidence, etiology, and prophylaxis. J Infect Dis 1991; 164(6): 1180–5
Levy M, Koren G, Dupuis L, et al. Vancomycin-induced redman syndrome. Pediatrics 1990; 86: 572–80
Odio C, Mohs E, Sklar FH, et al. Adverse reactions to vancomycin used as prophylaxis for CSF shunt procedures. Am J Dis Child 1984; 138(1): 17–9
Lacouture PG, Epstein MF, Mitchell AA, et al. Vancomycin-associated shock and rash in newborn infants. J Pediatr 1987; 11: 615–6
Boussemart T, Cardona J, Berthier M, et al. Cardiac arrest associated with vancomycin in a neonate [letter]. Arch Dis Child 1995; 73 (F Suppl.): 123S
Moller JC, Nachtrod G, Tegtmeyer FK, et al. Prophylactic low-dose vancomycin treatment in very-low-birthweight infants. Dev Pharmacol Ther 1992; 19: 178–82
Cooke RW, Nycyk JA, Okuonghnae H, et al. Low dose vancomycin prophylaxis reduces coagulase-negative staphylococcal bacteriemia in very low birth weight infants. J Hosp Infect 1997; 37(4): 297–303
Bayer RS, Bocchini Jr JA, Brown EG. Selective use of vancomycin to prevent coagulase-negative staphylococcal nosocomial bacteriemia in high risk very low birth weight infants. Pediatr Infect Dis J 1998; 17(3): 179–83
Krediet TG, Fleer A. Should we use vancomycin as prophylaxis to prevent neonatal nosocomial coagulase-negative staphylococcal septicemia? Pediatr Infect Dis J 1998 Aug; 17(8): 763–4
Hall SL. Coagulase-negative staphylococcal infections in neonates. Pediatr Infect Dis J 1991; 10: 57–67
Noel GJ, Edelson PJ. Staphylococcus epidermidis bacteriemia in neonates: further observations and the occurrence of focal infections. Pediatrics 1984; 74: 832–7
Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209–22
Lewis P, Geroud JJ, Parenti F. A multicenter open clinical trial of teicoplanin infections caused by gram-positive bacteria. J Antimicrob Chemother 1996; A Suppl.: 61S–67S
Kacet N, Dubois JP, Roussel-Delvallez M, et al. Teicoplanin and amikacin in neonates with staphylococcal infection. Pediatr Infect Dis J 1993; 12 Suppl.: 10–20
Serra G, Giovanni L, Bonacci W. Staphylococcal infections in the neonatal period [in Italian]. Antibiotic Prat 1992; 2: 45–53
Guadagni AM, Quondamcarlo A, Mosconi G. Neonatal staphylococcal infections treated with teicoplanin. J Chemother 1993; 5 Suppl.: 485–7
Tuo P, Tumolo M, Silvestri G. Teicoplanin therapy in neonatal and pediatric intensive care units [in Italian]. Med Surg Pediatr 1992; 151–4
Padovani EM, Khoory BJ, Beghini R, et al Teicoplanin: clinical efficacy, antibacterial activity and tolerance in the treatment of staphylococcal infections in the newborn. Ann Exp Clin Med 1994; 1: 111–5
Campoli-Richards DM, Brodgen RN, Faulds D. Teicoplanin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1990; 40: 449–86
Antony KK, Lewis EV, Kenny MT, et al. Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans. J Pharm Sci 1991; 80: 605–7
Brodgen RN, Peters DH. Teicoplanin: a reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 823–54
Dagan R, Einhorm SI, Howard CB, et al. Outpatient and inpatient teicoplanin treatment for serious gram-positive infections in children. Pediatr Infect Dis J 1993; 12 Suppl.: 17S–20S
Peller P, Aichzolzen B, Fell J, et al. Safety and efficacy of teicoplanin in the treatment of gram-positive infection in pediatric patients in Germany. Pediatr Infect Dis J 1993; 12 Suppl.: 17S–20S
Moller JC, Nelskamp I, Jensen R, et al. Teicoplanin pharmacology in prophylaxis for coagulase-negative staphylococcal sepsis of very low birthweight infants. Acta Paediatr 1996; 85: 638–40
Degraeuwe PL, Beuman GH, van Triel FH, et al. Use of teicoplanin in preterm neonates with staphylococcal late-onset neonatal sepsis. Biol Neonate 1998; 75(3): 287–95
Fanos V, Mussap M, Khoory BJ, et al. Renal tolerability of teicoplanin in a case of neonatal overdose. J Chemother 1998 Oct; 10(5): 381–4
Laferriere CL, Marks MI. Chloramphenicol properties and clinical use. Pediatr Infect Dis J 1982 Jul; 1(4): 257–64
Shann F. The management of pneumonia in children in developing countries. Clin Infect Dis 1995 Dec; 21 (3 Suppl.) 218S–225S
Adikari M, Coovadie YM, Siugh D. A 4-year study of neonatal meningitis: clinical and microbiological findings. J Trop Pediatr 1995 Apr; 41(2): 81–5
Rajchgot P, Prober CG, Soldin S, et al. Initiation of chloramphenicol therapy in the newborn infant. J Pediatr 1982 Dec; 101(6): 1018–21
Nahata MC, Powell DA. Comparative bioavailability and pharmacokinetics of chloramphenicol after intravenous chloramphenicol succinate in premature infants and older patients. Dev Pharmacol Ther 1983 Jan; 6(5): 23–32
Rajchgot P, Prober C, Soldin S, et al. Chloramphenicol pharmacokinetics in the newborn. Dev Pharmacol Ther 1983 Jan; 6(5): 305–14
Mulhall A, de Louvois J, Hurley R. The pharmacokinetics of chloramphenicol in the neonate and young infant. J Antimicrob Chemother 1983 Dec; 12(6): 629–39
Ristuccia AM. Chloramphenicol: clinical pharmacology in pediatrics. Ther Drug Monit 1985 Jan; 72(2): 159–67
Shankaran S, Kauffman RE. Use of chloramphenicol palmitate in neonates. Pediatr 1984 Jul; 105(1): 113–6
Mulhall A, de Louvois J, Hurley R. Chloramphenicol toxicity in neonates: its incidence and prevention. BMJ 1983 Nov; 287(6403): 1424–7
Mulhall A, Berry DJ, de Louvois J. Chloramphenicol in pediatrics: current prescribing practice and the need to monitor. Eur J Pediatr 1988 Aug; 147(6): 574–8
Sabel KG, Brandberg A. Treatment of meningitis and septicemia in infancy with a trimethoprim-sulfamethoxazole combination. Acta Pediatr Scand 1975; 54: 25
Ardati KO, Thirumoorthi MC, Dajani AS. Intravenous trimethoprim-sulfamethoxazole in the treatment of serious infections in children. J Pediatr 1979 Nov; 95 (5 Pt 1): 801–6
Janner D, Bork J, Baum M, et al. Pneumocystis carinii pneumonia in infants after heart transplantation. J Heart Lung Transplant 1996 Aug; 15(8): 758–63
Bang AT, Bang RA, Morankar VP, et al. Pneumonia in neonates: can it be managed in the community? Arch Dis Child 1993 May; 68 (5 Spec. No.): 550–6
Butler DR, Kuhn RJ, Chandler MH. Pharmacokinetics of antiinfective agents in paediatric patients. Clin Pharmacokinet 1994 May; 26(5): 374–95
Springer C, Eyal F, Michel J. Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. J Pediatr 1982 Apr; 100(4): 647–50
Walker PC. Neonatal bilirubin toxicity: a review of kernicterus and the implications of drug-induced bilirubin displacement. Clin Pharmacokinet 1987; 13(1): 26–50
Perazzella M, Mahnemanit R. Trimethroprim-sulfamethoxazole hyperkaliemia is an important complication regardless of the dose. Clin Nephrol 1996; 48: 187–92
Washington JA, Wilson WR. Erythromycin: a microbial and clinical perspective after 30 years of clinical use. Mayo Clin Proc 1985 Apr; 60(4): 271–8
Waites KB, Sims PJ, Crouse DT, et al. Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for Ureaplasma urealyticum infection. Pediatr Infect Dis J 1994 Apr; 13(4): 287–93
Stenberg K, Mardh PA. Treatment of chlamydial conjunctivitis in newborns and adults with erythromycin and roxithromycin. J Antimicrob Chemother 1991 Aug; 28(2): 301–7
Burns L, Hodgman J. Studies of prematures given erythromycin estolate. Am J Dis Child 1963; 106: 280–4
Patamasucon P, Kaojarern S, Kusmiesz H, et al. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age. Antimicrob Agents Chemother 1981; 19: 736–40
Krowchuk D, Seashore JH. Complete biliary obstruction due to erythromycin estolate administration in an infant. Pediatrics 1979 Dec; 64(6): 956–8
Sims PJ, Waites KB, Crouse DT. Erythromycin lactobionate toxicity in preterm neonates. Pediatr Infect Dis J 1994 Feb; 13(2): 164–7
Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985 Jan; 10(1): 63–79
Martin C, Bontegeat G, Bildstein G, et al. Evolution of congenital toxoplasmosis. Critical study on 12 treated cases [in French]. Ann Pediatr 1969; 16: 117–28
Waites KB, Crouse DT, Cassell GH. Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates. Pediatr Infect Dis J 1992 Jan; 11(1): 23–9
Koren G, Zarfin Y, Maresky D, et al. Pharmacokinetics of intravenous clindamycin in newborn infants. Pediatr Pharmacol 1986 Jan; 5(4): 287–92
Le Frock JL, Molavi A, Prince RA. Clindamycin. Med Clin North Am 1982 Jan; 66(1): 103–20
Tan TQ, Mason Jr EO, Ou CN, et al. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother 1993 Nov; 37(11): 2401–6
Zinner SH, Lagast H, Klastersky J. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis 1981 Oct; 144(4): 365–71
Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978 Mar–Apr; 3(2): 108–27
Martell M, de Ben S, Weinberger M. Growth and development in preterm infants receiving fluoroquinolones. J Perinat Med 1996; 24(3): 287–91
Lumbiganon P, Pengsaa K, Sookpranee T. Ciprofloxacin in neonates and its possible adverse effect on the teeth. Pediatr Infect Dis J 1991 Aug; 10(8): 619–20
van den Oever HL, Versteegh FG, Thewessen EA, et al. Ciprofloxacin in preterm neonates: case report and review of the literature. Eur J Pediatr 1998 Oct; 157(10): 843–5
Rosenblatt JE, Edson RS. Metronidazole. Mayo Clin Proc 1987 Mar; 58(3): 154–7
Jager RE, Doyle PE, Baird LJ, et al. Pharmacokinetics and tissue distribution of metronidazole in the newborn infant. J Pediatr 1982 Apr; 100(4): 651–4
Upadhyaya P, Bhatnajar V, Basu N. Pharmacokinetics of intravenous metronidazole in neonates. J Pediatr Surg 1988 Mar; 23(3): 263–5
Lam YWM, Banerji S, Hatfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997 Jan; 32(1): 30–57
Trompeter R. A review of drug prescribing in children with end stage renal disease. Pediatr Nephrol 1987; 1: 183–94
Wong AK, Bolinger AM, Gambertaglio JG. Pharmacokinetics and drug dosing in children with decreased renal function. In: Holliday MA, Barrat TM, Avner ED, editors. Pediatric nephrology. 3rd ed. Baltimore (MD): William and Wilkins, 1994: 1305–13
Fanos V, Khoory BJ, Cataldi L. Drug-induced nephrotoxicity in the newborn. In: Cataldi L, Fanos V, Simeoni U. Neonatal nephrology in practice [in Italian]. Lecce: Agorà, 1996: 241–74
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fanos, V., Dall’Agnola, A. Antibiotics in Neonatal Infections. Drugs 58, 405–427 (1999). https://doi.org/10.2165/00003495-199958030-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199958030-00003